Pathology & Oncology Research

, Volume 11, Issue 1, pp 5–10 | Cite as

Genomics of lung cancer may change diagnosis, prognosis and therapy

  • László Kopper
  • József Tímár


Despite significant improvements in tumor management in general, the prognosis of lung cancer patients remains dismal. It is a hope that our increasing knowledge in molecular aspects of tumor development, growth and progression will open new targets for therapeutic interventions. In this review we discuss some of the more recent results of this field. This includes the susceptibility factors, an association between genetic changes in EGFR pathway and tyrosine kinase inhibitors, the role of gene hypermethylation and genetic profiling, as well as different molecular aspects of tumor progression. Available data all support that lung cancer is a group of diseases with not only distinct histological but with similarly different genetic characters. Accordingly, the diagnosis, prognosis and therapy must accommodate this heterogeneity.

Key words

lung cancer genomics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schwartz AG: Genetic predisposition to lung cancer. Chest 125: 86S-89S, 2004PubMedCrossRefGoogle Scholar
  2. 2.
    Olak J, Colson Y: Gender differences in lung cancer: Have we really come a long way, baby? J Thorac Cardiovasc Surg 128: 346–351, 2004PubMedCrossRefGoogle Scholar
  3. 3.
    Minna JD, Roth JA, Gazdar AF: Focus on lung cancer. Cancer Cell 1: 49–52, 2002PubMedCrossRefGoogle Scholar
  4. 4.
    Balsara BR, Testa JR: Chromosomal imbalances in human lung cancer. Oncogene 21: 6877–6883, 2002PubMedCrossRefGoogle Scholar
  5. 5.
    Yokota J, Kohno T: Molecular footprints of human lung cancer progression. Cancer Sci 95: 197–204, 2004PubMedCrossRefGoogle Scholar
  6. 6.
    Kazanjian A, Wallis D, Au N, et al: Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Res 64: 3874–6882, 2004CrossRefGoogle Scholar
  7. 7.
    Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857–865, 2005PubMedCrossRefGoogle Scholar
  8. 8.
    Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139, 2004PubMedCrossRefGoogle Scholar
  9. 9.
    Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500, 2004PubMedCrossRefGoogle Scholar
  10. 10.
    Amann J, Kalyankrishna S, Massion PP, et al: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226–235, 2005PubMedGoogle Scholar
  11. 11.
    Cancer Genome Project and Collaborative Group. Nature 431: 525–526, 2004Google Scholar
  12. 12.
    West KA, Linnoila IR, Brognard J, et al: Tobacco carcinogeninduced cellular transformation increases Akt activation in vitro and in vivo. Chest 125: 101S-102S, 2004PubMedCrossRefGoogle Scholar
  13. 13.
    De Benedetti A, Graff JR: eIF expression and its role in malignancies and metastases. Oncogene 23: 3189–3199, 2004PubMedCrossRefGoogle Scholar
  14. 14.
    Sugita M, Geraci M, Gao B, et al: Combined use of oligonucleotide and tissue microarray identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62: 3971–3979, 2002PubMedGoogle Scholar
  15. 15.
    Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Rev Cancer 4: 707–717, 2004CrossRefGoogle Scholar
  16. 16.
    Mazieres J, He B, You L, et al: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in lung cancer. Cancer Res 64: 4717–4720, 2004PubMedCrossRefGoogle Scholar
  17. 17.
    Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784–13789, 2001PubMedCrossRefGoogle Scholar
  18. 18.
    Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790–13795, 2001PubMedCrossRefGoogle Scholar
  19. 19.
    Wigle DA, Jurisica I, Radulovich N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62: 3005–3008, 2002PubMedGoogle Scholar
  20. 20.
    Kaminski N, Krupsky M: Gene expression patterns, prognostic and diagnostic markers, and lung cancer biology. Chest 125: 111S-115S, 2004PubMedCrossRefGoogle Scholar
  21. 21.
    Beer DG, Kardia SL, Huang CC, et al: Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816–824, 2002PubMedGoogle Scholar
  22. 22.
    Gordon GJ, Jensen RV, Hsiao LL, et al: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62: 4963–4967, 2002PubMedGoogle Scholar
  23. 23.
    Martin B, Paesmans M, Mascaux C et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91:2018–2025, 2004PubMedCrossRefGoogle Scholar
  24. 24.
    Lu C, Soria J-C, Tang X, et al: Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22:4575–4583, 2004PubMedCrossRefGoogle Scholar
  25. 2 5.
    Mehdi SA, Tatum AH, Newman NB et al: Prognostic markers in resected stage I and II non-small-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer 1:59–67, 1999PubMedCrossRefGoogle Scholar
  26. 26.
    Masuya D, Huang C, Liu D, et al: The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in nonsmall-cell lung cancer patients. Br J Cancer 90:1555–1562, 2004PubMedCrossRefGoogle Scholar
  27. 27.
    Fukuoka J, Fujii T, Shih JH et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in nonsmall cell lung cancer. Clin Cancer Res 10:4314–4324, 2004PubMedCrossRefGoogle Scholar
  28. 28.
    Goncharuk VN, Del-Rosario A, Kren L et al: Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Ann Diagn Pathol 8:6–16, 2004PubMedCrossRefGoogle Scholar
  29. 29.
    Diederichs S, Bulk E, Steffen B et al: S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64:5564–5569, 2004PubMedCrossRefGoogle Scholar
  30. 30.
    Simi L, Andreani M, Davini F et al: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45:171–179, 2004PubMedCrossRefGoogle Scholar
  31. 31.
    Takahashi H, Ebihara S, Okazaki T et al: Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer 45:207–214, 2004PubMedCrossRefGoogle Scholar
  32. 32.
    Shah L, Walter KL, Borczuk AC et al: Expression of Syndecan1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632–1638, 2004PubMedCrossRefGoogle Scholar
  33. 33.
    O-charoenrat P, Rusch V, Talbot SG et al: Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10:5709–5803, 2004CrossRefGoogle Scholar
  34. 34.
    Au NHC, Cheang M, Huntsman DG et al: Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 204:101–109, 2004PubMedCrossRefGoogle Scholar
  35. 35.
    Shabman MS, Srinivasan R, Wali A et al: Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of he lung. Lung Cancer 45:181–188, 2004CrossRefGoogle Scholar
  36. 36.
    Toledo G, Sola JJ, Lorenzo MD et al: Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung carcinoma. Mod Pathol 17:440–448, 2004PubMedCrossRefGoogle Scholar
  37. 37.
    Aljada IS, Rammath N, Donohue K et al: Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 22:3218–3229, 2004PubMedCrossRefGoogle Scholar
  38. 38.
    Tsutsumida H, Goto M, Kitajima S et al: Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 44: 147–155, 2004PubMedCrossRefGoogle Scholar
  39. 39.
    Ramaswamy S, Ross KN, Lander ES, Golub H: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54, 2003PubMedCrossRefGoogle Scholar
  40. 40.
    Araki K, Hashimoto K, Ardyanto TD, et al: Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 45:161–169, 2004PubMedCrossRefGoogle Scholar
  41. 41.
    Yamaguchi NH, Lichtens AJ, Dmarchi LM et al: COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. Am J Clin Pathol 121:78–86, 2004PubMedCrossRefGoogle Scholar
  42. 42.
    Pelosi G, Barisella M, Pasini F et al: CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 17:711–721, 2004PubMedCrossRefGoogle Scholar
  43. 43.
    Jones MH, Virtanen C, Honjoh D et al: Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363:775–781, 2004PubMedCrossRefGoogle Scholar
  44. 44.
    Rohr U-P, Rehfeld N, Pflugfelder L et al: Expression of the tyrosine kinase C-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 111:159–263, 2004CrossRefGoogle Scholar
  45. 45.
    He P, Varticovski L, Bowman ED, et al: Identification of carboxypeptidase E and γ-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 35:1196–1209, 2004PubMedCrossRefGoogle Scholar
  46. 46.
    Koukourakis MI, Giatromanolaki A, Sivridis E et al: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small cell lung cancer tissues is linked to tumour hypoxia, angiogenetic factor production and poor prognosis. Br J Cancer 89:877–885, 2003PubMedCrossRefGoogle Scholar
  47. 47.
    Nakashima T, Huan C, Liu D et al: Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 10:BR157–165, 2004PubMedGoogle Scholar
  48. 48.
    Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T, Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardio-thoracic Surg 25:443–448, 2004CrossRefGoogle Scholar
  49. 49.
    Ogawa E, Takenaka K, Yanagihara K et al: Clinical significance of VEGF-C status in tumor cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 91:498–503, 2004PubMedCrossRefGoogle Scholar
  50. 50.
    Mineto TC, Ambrogi V, Baldi A et al: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung carcinoma. J Clin Pathol 57:591–597, 2004CrossRefGoogle Scholar
  51. 51.
    Tanaka F, Yanagihara K, Otake Y et al: Prognostic factors in resected pathologic (p−) stage IIIA-N2, non-small-cell lung carcinoma. Ann Surg Oncol 11:612–618, 2004PubMedCrossRefGoogle Scholar
  52. 52.
    Stefanou D, Batistatou A, Arkoumani E et al: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small cell lung carcinoma. Histol Histopathol 19:37–42, 2004PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2005

Authors and Affiliations

  1. 1.1st Institute of Pathology and Experimental Cancer ResearchSemmelweis UniversityBudapestHungary
  2. 2.Department of Tumor ProgressionNational Institute of OncologyBudapestHungary

Personalised recommendations